查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1735703

全球脊髓灰質炎疫苗市場規模（依脊髓灰質炎疫苗類型、應用、區域範圍、預測）

Global Polio Vaccine Market Size By Polio Vaccine Type, By Application, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

脊髓灰質炎疫苗市場規模及預測

2024 年脊髓灰質炎疫苗市場規模價值 6.995 億美元，預計到 2032 年將達到 10.6781 億美元，2026 年至 2032 年的複合年成長率為 4.6%。

全球脊髓灰質炎疫苗市場促進因素

脊髓灰質炎疫苗市場的市場促進因素可能受到多種因素的影響，其中包括：

  • 政府努力和疫苗接種計劃 許多國家與聯合國兒童基金會和世界衛生組織 (WHO) 等國際組織合作開展了大規模疫苗宣傳活動，以消滅脊髓灰質炎，大大增加了對脊髓灰質炎疫苗的需求。
  • 部分地區脊髓灰質炎發生率上升：儘管國際社會做出了努力，但脊髓灰質炎仍在部分地區持續蔓延，尤其是在亞洲和非洲。各國正加強疫苗接種工作，以控制脊髓灰質炎並阻止其蔓延。
  • 疫苗技術發展：疫苗技術的新突破，例如更安全、更有效的疫苗的研發，正在推動市場擴張。新的給藥方式和疫苗配方的改進，是有助於提高疫苗接種率和有效性的一些進步。
  • 知識和醫療支出的增加：這個市場是由許多國家對疫苗接種價值的認知不斷加深以及醫療支出不斷增加所驅動的。隨著政府和非政府組織加強對醫療機構和疫苗接種計畫的投資，疫苗需求正在上升。
  • 全球根除脊髓灰質炎行動：像全球根除脊髓灰質炎行動 (GPEI) 這樣的組織透過為世界各地的免疫計畫提供資金和援助，在推動市場發展方面發揮著至關重要的作用。他們的工作對於維持高免疫接種率和追蹤脊髓灰質炎疫情至關重要。
  • 開發中國家出生率上升：開發中國家出生率上升導致符合脊髓灰質炎疫苗接種條件的目標人口增加。這一人口方面影響著脊髓灰質炎疫苗接種的持續需求。
  • 夥伴關係與合作：政府、非政府組織 (NGO) 和私營部門之間的合作可以提高脊髓灰質炎疫苗宣傳活動的有效性和涵蓋範圍，並有助於擴大市場。
  • 根除脊髓灰質炎的經濟效益：根除脊髓灰質炎具有降低醫療成本、提高生產力等經濟效益，鼓勵政府和組織投資疫苗接種計劃，進而增加市場需求。
  • 監管支持與核准：有利的新型疫苗法律規範以及美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 的快速核准，促進了該行業的擴張。監管支持確保了疫苗的及時分發和供應。

限制全球脊髓灰質炎疫苗市場的因素

脊髓灰質炎疫苗市場面臨許多阻礙因素和挑戰，包括：

  • 生產挑戰：生產脊髓灰質炎疫苗需要嚴格的品管和生物安全程序。任何干擾生產過程的因素，例如污染或設備故障，都可能導致供不應求。
  • 低溫運輸物流：脊髓灰質炎疫苗，尤其是口服脊髓灰質炎疫苗 (OPV)，必須在特定溫度下運輸和儲存才能保持有效。低溫運輸設施不足會使疫苗分發變得複雜，尤其是在低收入者身上。
  • 資金限制：脊髓灰質炎疫苗宣傳活動通常由政府和國際組織資助。資金不足可能會限制疫苗接種的覆蓋率和覆蓋範圍。
  • 疫苗接種計畫成本：疫苗接種計畫成本：實施大規模疫苗接種計畫會產生各種成本，包括人員配備、物流、公眾意識提升宣傳活動等。疫苗接種的頻率和覆蓋率可能會受到財務限制的影響。
  • 政治不穩定：在政治不穩定或暴力事件頻繁的地區，由於人口流動和安全問題，可能難以進行定期的大規模疫苗宣傳活動。
  • 疫苗猶豫：由於錯誤訊息和對疫苗接種的不信任，社區居民可能對疫苗接種猶豫不決。對疫苗有效性和安全性的誤解和文化觀念可能會降低疫苗接種率。
  • 監管部門核准：獲得全新疫苗或已核准疫苗的變更的監管部門批准是一個困難且漫長的過程。
  • 政策差異：各國的衛生政策和法律規範各不相同，這可能會使脊髓灰質炎免疫的國際分發和吸收變得複雜。
  • 新出現的健康危機：其他疾病（例如新冠肺炎）的爆發可能會導致脊髓灰質炎疫苗接種宣傳活動的關注和資金減少。衛生系統可能會優先考慮當前風險，而不是持續的根除脊髓灰質炎的努力。
  • 疫苗研發：研發新的改良的脊髓灰質炎疫苗，包括更容易接種和提供更持久免疫力的疫苗，成本高且技術難度高。
  • 技術創新停滯：高成本和風險問題可能會阻礙疫苗技術的創新，從而阻礙市場成長。
  • 近乎根除的挑戰：一旦脊髓灰質炎幾乎被徹底根除，人們可能不再願意接種疫苗，這可能導致疫苗接種率下降。

目錄

第1章 全球脊髓灰質炎疫苗市場簡介

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章 全球脊髓灰質炎疫苗市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

5. 全球脊髓灰質炎疫苗市場（以脊髓灰質炎疫苗類型）

  • 概述
  • 口服脊髓灰質炎疫苗（OPV）
  • 去活化脊髓灰質炎疫苗（IPV）

第6章 全球脊髓灰質炎疫苗市場（依應用）

  • 概述
  • 公共
  • 私人的

第7章全球脊髓灰質炎疫苗市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區
    • 拉丁美洲
    • 中東和非洲

8. 全球脊髓灰質炎疫苗市場的競爭格局

  • 概述
  • 各公司市場排名
  • 主要發展策略

第9章 公司簡介

  • Pfizer
  • GlaxoSmithKline
  • Sanofi
  • Astellas Pharma
  • Serum Institute of India Pvt. Ltd.
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Panacea Biotec Ltd

第10章 附錄

  • 相關調查
簡介目錄
Product Code: 35696

Polio Vaccine Market Size And Forecast

Polio Vaccine Market size is valued at USD 699.5 Million in the year 2024 and is projected to reach USD 1067.81 Million in 2032, growing at a CAGR of 4.6% from 2026 to 2032.

Global Polio Vaccine Market Drivers

The market drivers for the Polio Vaccine Market can be influenced by various factors. These may include:

  • Government Initiatives and Vaccination Programmes: In an effort to end polio, numerous nations have started massive vaccination campaigns in cooperation with international agencies like UNICEF and the World Health Organisation (WHO). The need for polio vaccines is greatly fueled by these initiatives.
  • Growing Polio Incidence in Some Areas: In spite of international efforts, polio outbreaks continue to happen, especially in some areas of Asia and Africa. Vaccination efforts are stepped up in response to these outbreaks in an attempt to contain and stop the disease's spread.
  • Technological Developments in Vaccines: New developments in vaccine technology, such as the creation of safer and more effective vaccinations, support market expansion. Novel delivery methods and improved vaccine formulations are examples of advances that increase immunisation uptake and efficacy.
  • Growing Knowledge and Healthcare Spending: The market is supported by growing knowledge of the value of vaccinations as well as growing healthcare spending in many nations. The demand for vaccines is rising as governments and non-governmental organisations invest more in healthcare facilities and immunisation programmes.
  • Global Polio Eradication Initiatives: By providing money and assistance for vaccination programmes worldwide, organisations such as the Global Polio Eradication Initiative (GPEI) are crucial in propelling the market. Their work is essential to keeping a high immunisation rate and tracking polio outbreaks.
  • Rising Birth Rates in Developing Nations: A greater target population for polio vaccination is produced by rising birth rates in developing nations. The ongoing need for polio immunisations is influenced by this demographic aspect.
  • Partnerships and Collaborations: Governments, non-governmental organisations (NGOs), and businesses in the private sector work together to improve the efficacy and reach of polio vaccine campaigns, which propels market expansion.
  • Economic Gains from Polio Eradication: Governments and organisations are encouraged to invest in vaccination programmes by the financial gains from polio eradication, which include lower healthcare expenses and increased productivity. This increases demand in the market.
  • Regulatory Support and Approvals: The expansion of the industry is facilitated by favourable regulatory frameworks and expedited FDA and EMA approvals for novel vaccines. The timely distribution and availability of vaccines is guaranteed by regulatory support.

Global Polio Vaccine Market Restraints

Several factors can act as restraints or challenges for the Polio Vaccine Market . These may include:

  • Manufacturing Difficulties: Strict quality control and biosafety procedures are needed during the production of polio vaccines. Shortages of supplies can result from any interference with the manufacturing process, including contamination and equipment malfunctions.
  • Cold Chain Logistics: To preserve their effectiveness, polio vaccines, especially the oral polio vaccine (OPV), must be transported and stored at a certain temperature. Inadequate cold chain facilities can make it more difficult to distribute vaccines, particularly in low-income areas.
  • Financial Restraints: Governments and international organisations are frequently the source of funding for polio immunisation campaigns. The extent of immunisation efforts and the availability of vaccinations may be restricted by a lack of financing.
  • Cost of Vaccination Programmes: The expenses associated with putting in place extensive vaccination programmes, such as those related to staffing, logistics, and public awareness campaigns, can add up. The frequency and reach of vaccination drives might be impacted by financial limitations.
  • Political Instability: Because of population dislocation and security concerns, areas undergoing political unrest or violence may find it challenging to implement regular and extensive vaccination campaigns.
  • Vaccine hesitation: In communities, vaccine hesitation can be caused by misinformation and mistrust of vaccinations. Misconceptions and cultural beliefs regarding the effectiveness and safety of vaccinations can lower vaccination rates.
  • Regulatory Approvals: Getting regulatory permission for brand-new vaccines or modifications to already-approved ones may be a difficult and drawn-out procedure, which may cause a delay in the product's release onto the market.
  • Policy Variations: Health policies and regulatory frameworks differ among nations, which might make it more difficult for polio vaccinations to be distributed and accepted internationally.
  • Emerging Health Crises: Polio vaccination campaigns may receive less attention and funding as a result of outbreaks of other diseases like COVID-19. Health systems can give priority to current risks over ongoing efforts to eradicate polio.
  • Vaccine Development: It can be expensive and technically difficult to create new and improved polio vaccines, such as those that offer easier administration or longer-lasting immunity.
  • Innovation Stagnation: The market's ability to grow may be hampered by a lack of innovation in vaccination technology as a result of high costs and risk issues.
  • Challenges associated with near-eradication: As polio is almost completely eradicated, people may become less inclined to get vaccinated, which could result in a decline in vaccination rates. There is a chance that this will resurface.

Global Polio Vaccine Market Segmentation Analysis

The Global Polio Vaccine Market is Segmented on the basis of Polio Vaccine Type, Application, and Geography.

Polio Vaccine Market, By Polio Vaccine Type

  • Oral Polio Vaccine (OPV)
  • Inactivated Poliomyelitis Vaccine (IPV)
  • Based on Polio Vaccine Type, the market is bifurcated into, Oral Polio Vaccine (OPV), Inactivated Poliomyelitis Vaccine (IPV). OralPolio Vaccine is leading in the segment used in the fight to eradicate polio and it can replicate effectively in the intestine which enables an individual to mount an immune response against the virus

Polio Vaccine Market, By Application

  • Public
  • Private
  • Based on Application, the market is bifurcated into the public and private segments. The public segment is estimated to hold the largest share. Government policies and their fight to eradicate polio has been the major cause for the growth of the segment

Polio Vaccine Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Geography, the Global Polio Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Asia Pacific region is leading in the segment and holds the largest industry in the globe, as the number of polio vaccination is highest in the region. North America and Europe also hold a decent amount of share in the market

Key Players

  • The major players in the Polio Vaccine Market are:
  • Pfizer
  • Sanofi, Astellas Pharma
  • Serum Institute of India Pvt. Ltd.
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Panacea Biotec Ltd.
  • GlaxoSmithKline (UK)
  • Bharat Biotech (India)
  • China National Biotec Group (China)
  • Walvax Biotechnology Co., Ltd. (China)
  • IMVAM (Canada)

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL POLIO VACCINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL POLIO VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL POLIO VACCINE MARKET, BY POLIO VACCINE TYPE

  • 5.1 Overview
  • 5.2 Oral Polio Vaccine (OPV)
  • 5.3 Inactivated Poliomyelitis Vaccine (IPV)

6 GLOBAL POLIO VACCINE MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Public
  • 6.3 Private

7 GLOBAL POLIO VACCINE MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East And Africa

8 GLOBAL POLIO VACCINE MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Pfizer
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 GlaxoSmithKline
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Sanofi
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Astellas Pharma
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Serum Institute of India Pvt. Ltd.
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Haffkine Bio-Pharmaceutical Corporation Ltd.
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Panacea Biotec Ltd
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments

10 Appendix

  • 10.1 Related Research